News
A phase 3 trial suggests reducing the use of cisplatin when treating nasopharyngeal carcinoma with toripalimab-based ...
Lisocabtagene maraleucel shows superior 3-year outcomes over standard care in second-line large B-cell lymphoma.
TipRanks on MSN2d
Gilead Sciences’ Promising Phase 3 Study in Lung Cancer Treatment
Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...
The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback